Hiroki Goto
Research Subjects
Hiroki Goto has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Naoya Wada
Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan
13 shared publications - Tomoko Shibutani
Translational Research Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan
13 shared publications - Akihito Kawazoe
Department of Gastroenterology and Gastrointestinal oncology National Cancer Center Hospital East Chiba Japan
8 shared publications - Fumitaka Suto
Daiichi Sankyo Inc., Basking Ridge, USA
8 shared publications - Hiroyoshi Nishikawa
Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan
8 shared publications - Kenji Nakamaru
Translational Science Department I, Precision Medicine Function, Daiichi Sankyo, Co., Ltd., Tokyo, Japan
8 shared publications
Latest Publications
- Open Access
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Tables from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Supplementary Figures and Tables.
- 13 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Tables from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Supplementary Figures and Tables.
- Open Access
Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard therapies for EGFR-mutated non-small-cell lung cancer (NSCLC); however, their efficacy is inconsistent. Secondary mutations in the EGFR or other genes that lead to resistance have been identified, but resistance mechanisms have not been fully identified. Chromosomal instability (CIN) is a hallmark of cancer and results in genetic diversity. In this study, we demonstrated by transcriptomic analysis that CIN activates the cGAS–STING signaling pathway, which leads to EGFR-TKI refractoriness in a subset of EGFR-mutated NSCLC patients. Furthermore, EGFR-mutated H1975dnMCAK cells, which frequently underwent chromosomal mis-segregation, demonstrated refractoriness to the EGFR-TKI osimertinib compared to control cells. Second, H1975dnMCAK cells exhibited activation of cGAS–STING signaling and its downstream signaling, including tumor-promoting cytokine IL-6. Finally, chromosomally unstable EGFR-mutated NSCLC exhibited enhanced epithelial–mesenchymal transition (EMT). Blockade of cGAS–STING-TBK1 signaling reversed EMT, resulting in restored susceptibility to EGFR-TKIs in vitro and in vivo. These results suggest that CIN may lead to the activation of cGAS–STING signaling in some EGFR-mutated NSCLC, resulting in EMT-associated EGFR-TKI resistance.
Open AccessChromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard therapies for EGFR-mutated non-small-cell lung cancer (NSCLC); however, their efficacy is inconsistent. Secondary mutations in the EGFR or other genes that lead to resistance have been identified, but resistance mechanisms have not been fully identified. Chromosomal instability (CIN) is a hallmark of cancer and results in genetic diversity. In this study, we demonstrated by transcriptomic analysis that CIN activates the cGAS–STING signaling pathway, which leads to EGFR-TKI refractoriness in a subset of EGFR-mutated NSCLC patients. Furthermore, EGFR-mutated H1975dnMCAK cells, which frequently underwent chromosomal mis-segregation, demonstrated refractoriness to the EGFR-TKI osimertinib compared to control cells. Second, H1975dnMCAK cells exhibited activation of cGAS–STING signaling and its downstream signaling, including tumor-promoting cytokine IL-6. Finally, chromosomally unstable EGFR-mutated NSCLC exhibited enhanced epithelial–mesenchymal transition (EMT). Blockade of cGAS–STING-TBK1 signaling reversed EMT, resulting in restored susceptibility to EGFR-TKIs in vitro and in vivo. These results suggest that CIN may lead to the activation of cGAS–STING signaling in some EGFR-mutated NSCLC, resulting in EMT-associated EGFR-TKI resistance.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Data from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody–drug conjugate with a topoisomerase I inhibitor connected by a cleavable linker, has been approved for patients with HER2-positive gastric or gastroesophageal junction tumors. This biomarker study assessed HER2 expression and immune cell infiltration in relation to the therapeutic response to T-DXd. This retrospective analysis included samples from patients treated with T-DXd in three clinical trials. We performed RNA sequencing and multiplex IHC on archival tumor samples obtained at baseline, during treatment, and after treatment. Flow cytometry was performed on tumor-infiltrating immune cells freshly isolated from tumor tissues. Samples from 28 patients were included in this study. ERBB2 mRNA levels and CD20+ cell infiltration in tumors were significantly higher at baseline in responders than in nonresponders. Patients were classified into three biological groups based on their baseline tumor/stroma-infiltrating immune cell densities. Two groups reported similar response rates, but a trend was observed toward a shorter progression-free survival in the group with more immunosuppressive regulatory T cells and PD-L1 expression at baseline. T-DXd treatment tended to increase the levels of tumor-infiltrating CD8+ T cells and PD1+CD8+ T cells, particularly in responders. Gene expression signatures of CTL and Th cells increased during treatment, whereas signatures related to hypoxia, MYC targets, collagen formation, and IL-10 were downregulated. Our data suggest that HER2 expression levels and baseline tumor microenvironment characteristics correlate with T-DXd efficacy. Furthermore, this treatment may modulate tumor microenvironment immune profiles. Further validation using a larger sample size is warranted.Significance:This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that HER2 expression levels and tumor characteristics before the initiation of T-DXd may correlate with the efficacy of the drug.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody–drug conjugate with a topoisomerase I inhibitor connected by a cleavable linker, has been approved for patients with HER2-positive gastric or gastroesophageal junction tumors. This biomarker study assessed HER2 expression and immune cell infiltration in relation to the therapeutic response to T-DXd. This retrospective analysis included samples from patients treated with T-DXd in three clinical trials. We performed RNA sequencing and multiplex IHC on archival tumor samples obtained at baseline, during treatment, and after treatment. Flow cytometry was performed on tumor-infiltrating immune cells freshly isolated from tumor tissues. Samples from 28 patients were included in this study. ERBB2 mRNA levels and CD20+ cell infiltration in tumors were significantly higher at baseline in responders than in nonresponders. Patients were classified into three biological groups based on their baseline tumor/stroma-infiltrating immune cell densities. Two groups reported similar response rates, but a trend was observed toward a shorter progression-free survival in the group with more immunosuppressive regulatory T cells and PD-L1 expression at baseline. T-DXd treatment tended to increase the levels of tumor-infiltrating CD8+ T cells and PD1+CD8+ T cells, particularly in responders. Gene expression signatures of CTL and Th cells increased during treatment, whereas signatures related to hypoxia, MYC targets, collagen formation, and IL-10 were downregulated. Our data suggest that HER2 expression levels and baseline tumor microenvironment characteristics correlate with T-DXd efficacy. Furthermore, this treatment may modulate tumor microenvironment immune profiles. Further validation using a larger sample size is warranted.Significance:This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that HER2 expression levels and tumor characteristics before the initiation of T-DXd may correlate with the efficacy of the drug.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Immune infiltration in tumors at baseline and association with response to T-DXd therapy. A, Tumoral CD8+ cell densities, as determined using mIHC, at baseline in responders and nonresponders. B, CD8A and CD8B mRNA expression levels, as determined using RNA-seq, in responders and nonresponders. CPM, counts per million. C, Relationship between immune cell densities for cells expressing CD4, CD68, CD20, CD163, CD208, and CD1a, as determined using mIHC and IHC. D, Relationship between immune cell densities and T-DXd efficacy. Patients with high vs. low immune cell densities were grouped based on the median value.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Immune infiltration in tumors at baseline and association with response to T-DXd therapy. A, Tumoral CD8+ cell densities, as determined using mIHC, at baseline in responders and nonresponders. B, CD8A and CD8B mRNA expression levels, as determined using RNA-seq, in responders and nonresponders. CPM, counts per million. C, Relationship between immune cell densities for cells expressing CD4, CD68, CD20, CD163, CD208, and CD1a, as determined using mIHC and IHC. D, Relationship between immune cell densities and T-DXd efficacy. Patients with high vs. low immune cell densities were grouped based on the median value.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Unsupervised hierarchical clustering analysis based on cell densities of evaluated immune cells at baseline. A, Heatmap depicting unsupervised hierarchical clustering results and characteristics of the three observed groups. B, ERBB2 expression levels in the three groups obtained from clustering. C, Kaplan–Meier OS and PFS curves of groups 1, 2, and 3 grouped by unsupervised hierarchical clustering based on cell densities of the evaluated immune cells. CPM, counts per million; ECOG PS, Eastern Cooperative Oncology Group performance status; I/O, immunotherapy.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Unsupervised hierarchical clustering analysis based on cell densities of evaluated immune cells at baseline. A, Heatmap depicting unsupervised hierarchical clustering results and characteristics of the three observed groups. B, ERBB2 expression levels in the three groups obtained from clustering. C, Kaplan–Meier OS and PFS curves of groups 1, 2, and 3 grouped by unsupervised hierarchical clustering based on cell densities of the evaluated immune cells. CPM, counts per million; ECOG PS, Eastern Cooperative Oncology Group performance status; I/O, immunotherapy.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Tumor-infiltrating immune cell densities at baseline and in response to T-DXd therapy in responders and nonresponders. A, Tumor-infiltrating CD8+ T-cell densities, as determined using mIHC. B, Tumoral CD8A and CD8B expression, as determined using RNA-seq. C, Percentage of CD8+ cells in CD3+ at baseline, as determined using FCM. D, Densities of eTregs (Fr2) and PD-1+CD8+ T cells and the CD8+ T-cell/eTreg ratio (Fr2). BL, baseline; CPM, copies per million; eTreg, effector Treg; OnT, on treatment.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Tumor-infiltrating immune cell densities at baseline and in response to T-DXd therapy in responders and nonresponders. A, Tumor-infiltrating CD8+ T-cell densities, as determined using mIHC. B, Tumoral CD8A and CD8B expression, as determined using RNA-seq. C, Percentage of CD8+ cells in CD3+ at baseline, as determined using FCM. D, Densities of eTregs (Fr2) and PD-1+CD8+ T cells and the CD8+ T-cell/eTreg ratio (Fr2). BL, baseline; CPM, copies per million; eTreg, effector Treg; OnT, on treatment.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures and Tables from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Supplementary Figures and Tables.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures and Tables from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Supplementary Figures and Tables.
- Open Access
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Associations between pretreatment HER2 expression levels and therapy response to T-DXd. A, ERBB2 mRNA expression levels, as determined using RNA-seq. B, HER2 H-score, as determined using IHC. CPM, counts per million; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
- 14 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Associations between pretreatment HER2 expression levels and therapy response to T-DXd. A, ERBB2 mRNA expression levels, as determined using RNA-seq. B, HER2 H-score, as determined using IHC. CPM, counts per million; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
- Open Access
- 1 January 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 5  (1) , 84-93
The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody–drug conjugate with a topoisomerase I inhibitor connected by a cleavable linker, has been approved for patients with HER2-positive gastric or gastroesophageal junction tumors. This biomarker study assessed HER2 expression and immune cell infiltration in relation to the therapeutic response to T-DXd. This retrospective analysis included samples from patients treated with T-DXd in three clinical trials. We performed RNA sequencing and multiplex IHC on archival tumor samples obtained at baseline, during treatment, and after treatment. Flow cytometry was performed on tumor-infiltrating immune cells freshly isolated from tumor tissues. Samples from 28 patients were included in this study. ERBB2 mRNA levels and CD20+ cell infiltration in tumors were significantly higher at baseline in responders than in nonresponders. Patients were classified into three biological groups based on their baseline tumor/stroma-infiltrating immune cell densities. Two groups reported similar response rates, but a trend was observed toward a shorter progression-free survival in the group with more immunosuppressive regulatory T cells and PD-L1 expression at baseline. T-DXd treatment tended to increase the levels of tumor-infiltrating CD8+ T cells and PD1+CD8+ T cells, particularly in responders. Gene expression signatures of CTL and Th cells increased during treatment, whereas signatures related to hypoxia, MYC targets, collagen formation, and IL-10 were downregulated. Our data suggest that HER2 expression levels and baseline tumor microenvironment characteristics correlate with T-DXd efficacy. Furthermore, this treatment may modulate tumor microenvironment immune profiles. Further validation using a larger sample size is warranted. Significance: This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that HER2 expression levels and tumor characteristics before the initiation of T-DXd may correlate with the efficacy of the drug.
- 1 January 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 5  (1) , 84-93
Open AccessThe Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer
Trastuzumab deruxtecan (T-DXd), an anti-HER2 antibody–drug conjugate with a topoisomerase I inhibitor connected by a cleavable linker, has been approved for patients with HER2-positive gastric or gastroesophageal junction tumors. This biomarker study assessed HER2 expression and immune cell infiltration in relation to the therapeutic response to T-DXd. This retrospective analysis included samples from patients treated with T-DXd in three clinical trials. We performed RNA sequencing and multiplex IHC on archival tumor samples obtained at baseline, during treatment, and after treatment. Flow cytometry was performed on tumor-infiltrating immune cells freshly isolated from tumor tissues. Samples from 28 patients were included in this study. ERBB2 mRNA levels and CD20+ cell infiltration in tumors were significantly higher at baseline in responders than in nonresponders. Patients were classified into three biological groups based on their baseline tumor/stroma-infiltrating immune cell densities. Two groups reported similar response rates, but a trend was observed toward a shorter progression-free survival in the group with more immunosuppressive regulatory T cells and PD-L1 expression at baseline. T-DXd treatment tended to increase the levels of tumor-infiltrating CD8+ T cells and PD1+CD8+ T cells, particularly in responders. Gene expression signatures of CTL and Th cells increased during treatment, whereas signatures related to hypoxia, MYC targets, collagen formation, and IL-10 were downregulated. Our data suggest that HER2 expression levels and baseline tumor microenvironment characteristics correlate with T-DXd efficacy. Furthermore, this treatment may modulate tumor microenvironment immune profiles. Further validation using a larger sample size is warranted. Significance: This biomarker study explored HER2 expression levels and immune cell characteristics that may affect response to T-DXd using tumor tissue samples collected from clinical trial participants. The results suggest that HER2 expression levels and tumor characteristics before the initiation of T-DXd may correlate with the efficacy of the drug.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Potent and Selective PTDSS1 Inhibitors Induce Collateral Lethality in Cancers with PTDSS2 Deletion
Targeting collateral deletion of housekeeping genes caused by the loss of tumor suppressor genes is a potential strategy to identify context-specific, molecular-targeted therapies in cancer. In mammals, phosphatidylserine (PS) synthesis depends on two redundant PS synthetases, PTDSS1 and PTDSS2, and PTDSS2 is located at a tumor-suppressive locus, 11p15.5. Here, we sought to determine whether PTDSS2 loss would confer vulnerability to disruption of PTDSS1 function. PTDSS2 was lost in a wide range of cancer types, and PTDSS1 depletion specifically suppressed growth in PTDSS2-deficient cancer cell lines. Potent and selective PTDSS1 inhibitors were developed whose activity phenocopied the effect of PTDSS1 depletion, and in vivo treatment of PTDSS2-deleted tumors with these inhibitors led to tumor regression. Whole-transcriptome analysis revealed that inhibition of PTDSS1 in PTDSS2-depleted cells activated the endoplasmic reticulum (ER) stress response downstream of PS depletion. ER stress-mediated cell death induced by PTDSS1 inhibitors activated tumor immunity through the secretion of HMGB1 protein followed by activation of bone marrow-derived dendritic cells. PTDSS2 loss showed intratumoral heterogeneity in clinical samples, raising concerns about resistance to PTDSS1 inhibition. However, the PTDSS1 inhibitor effectively suppressed the growth of tumor containing both PTDSS2 wild-type and knockout cells in immunocompetent mice, showing potency for overcoming tumor heterogeneity by modulating the tumor immune microenvironment. Thus, these newly developed PTDSS1 inhibitors provide a therapeutic option for treating cancer with PTDSS2 loss, harnessing the synthetic lethality of PTDSS1/2.Significance:This study identifies a specific dependency on PTDSS1 for phosphatidylserine synthesis following PTDSS2 deletion and introduces novel PTDSS1 inhibitors as a therapeutic option to induce collateral lethality in cancer with PTDSS2 loss.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Potent and Selective PTDSS1 Inhibitors Induce Collateral Lethality in Cancers with PTDSS2 Deletion
Targeting collateral deletion of housekeeping genes caused by the loss of tumor suppressor genes is a potential strategy to identify context-specific, molecular-targeted therapies in cancer. In mammals, phosphatidylserine (PS) synthesis depends on two redundant PS synthetases, PTDSS1 and PTDSS2, and PTDSS2 is located at a tumor-suppressive locus, 11p15.5. Here, we sought to determine whether PTDSS2 loss would confer vulnerability to disruption of PTDSS1 function. PTDSS2 was lost in a wide range of cancer types, and PTDSS1 depletion specifically suppressed growth in PTDSS2-deficient cancer cell lines. Potent and selective PTDSS1 inhibitors were developed whose activity phenocopied the effect of PTDSS1 depletion, and in vivo treatment of PTDSS2-deleted tumors with these inhibitors led to tumor regression. Whole-transcriptome analysis revealed that inhibition of PTDSS1 in PTDSS2-depleted cells activated the endoplasmic reticulum (ER) stress response downstream of PS depletion. ER stress-mediated cell death induced by PTDSS1 inhibitors activated tumor immunity through the secretion of HMGB1 protein followed by activation of bone marrow-derived dendritic cells. PTDSS2 loss showed intratumoral heterogeneity in clinical samples, raising concerns about resistance to PTDSS1 inhibition. However, the PTDSS1 inhibitor effectively suppressed the growth of tumor containing both PTDSS2 wild-type and knockout cells in immunocompetent mice, showing potency for overcoming tumor heterogeneity by modulating the tumor immune microenvironment. Thus, these newly developed PTDSS1 inhibitors provide a therapeutic option for treating cancer with PTDSS2 loss, harnessing the synthetic lethality of PTDSS1/2.Significance:This study identifies a specific dependency on PTDSS1 for phosphatidylserine synthesis following PTDSS2 deletion and introduces novel PTDSS1 inhibitors as a therapeutic option to induce collateral lethality in cancer with PTDSS2 loss.